|
| home > about us > executive team |
|
Executive Team
Prior to iCardiac Technologies Mr. Totterman was the Chief Operating Officer of VirtualScopics Inc. (VSCP), a leading developer of image-based biomarkers for improving pharmaceutical development. During his tenure at VirtualScopics, he lead several of rounds of venture capital funding as well as striking strategic investment relationships with Pfizer, Inc. and GE Healthcare. Additionally, he was instrumental in developing VirtualScopics original business plan and overseeing the growth of the organization. Earlier in his career, Mr. Totterman also served as a principal at 3Com Ventures, a $250 million venture capital fund based in Santa Clara, CA as well as building 3Com’s Network of Global Strategic Alliances with companies including Philips, Siemens, AT&T and British Telecom. He has also held positions at Boston Consulting Group as well as Gemini Consulting. Mr. Totterman received his Bachelors Degree in Engineering from Stanford University where he was a David Starr Jordan Scholar and his Masters of Business Administration from the Amos Tuck School at Dartmouth College.
Dr. Couderc is an internationally recognized authority in the development of computerized techniques for ECG signal evaluation in cardiac safety and Thorough QT (TQT studies). He is a founder and director of the Telemetric and Holter ECG Warehouse (THEW), a partnership between the Food and Drug Administration and the University of Rochester. The THEW serves as a platform for industry, academia and regulators to validate new methods for advancing the science and practice of conducting cardiac safety studies. Dr. Couderc has dedicated his career to quantitative electrocardiography focusing on the development and application of novel techniques for the analysis of ventricular repolarization from the surface ECG in human and in various animal models for clinical trials. Dr. Couderc is the author or co-author of numerous publications in computational science and engineering, numerical analysis, and computer science applied to electrophysiological signals. He is currently a member of the editorial boards of the Annals of Non-Invasive Electrocardiology and holds an SGE position at the Center for Drug Evaluation and Research for the US Food and Drug Administration. Dr. Couderc has participated in a wide range of clinical trials as well as being principal investigator and a co-investigator in several federally-funded research grants. He is a frequent lecturer at universities, laboratories, and industrial research centers in U.S and Europe involving industry and national agencies (NIH and EPA). Dr. Couderc obtained his PhD degree with highest honors from the French National Institute of Applied Sciences in Lyon, France. He was appointed Research Assistant Professor of Medicine in the Cardiology Department of Strong Memorial Hospital, University of Rochester Medical Center, NY and graduated as a Master of Business and Administration from the Simon School of Business of Rochester, NY. Additionally, he is the Assistant Director of the Heart Research Follow-up Program Laboratory, an international leader in the research of the long QT syndrome.
Dr. Zareba has over 27 years of expertise in Cardiology research. In addition to his position at iCardiac, Dr. Zareba is also a Professor of Medicine (Cardiology) at the University of Rochester Medical Center Rochester, NY. He is the Director of Clinical Research in the Medical Center’s Cardiology Unit and Director of the Heart Research Follow-Up Program. Dr. Zareba is Principal Investigator on several NIH and corporate grants focused on clinical usefulness and prognostic significance of ECG parameters and on risk stratification of sudden cardiac death. He also serves as Principal Investigator of the ECG Core Lab for numerous studies including the International LQTS Registry, the North American ARVD Registry, MADIT II, and MADIT-CRT, large clinical trials testing clinical effectiveness and safety of implantable cardiac defibrillators and resynchronization devices. He participated in a number of clinical research studies focused on evaluating drug safety with companies including Roche, Lorex, Pfizer, Warner-Lambert, Eli Lilly, Genzyme, and Bristol Meyers Squibb. He is an active participant in a number of advisory councils on the topic of cardiac safety in drug trials including ISHNE Standards for Drug-Induced QT Prolongation Analysis and FDA Panel on Digital ECG Format for Drug Studies. Dr Zareba has contributed, authored or co-authored more than 400 publications in cardiology research with many of them focused on QT prolongation and ECG related cardiac safety biomarkers. Dr. Zareba is the Editor in Chief of Cardiology Journal, Deputy Editor of Annals of Noninvasive Electrocardiology as well as a member of the editorial boards of a number of other leading cardiology-related publications including Journal of Cardiovascular Electrophysiology, Heart Rhythm Journal, Journal of Electrocardiology, and Journal of Arrhythmia. Dr. Zareba is President of the International Society for Holter and Noninvasive Electrocardiology. Dr. Zareba obtained his MD degree in Medicine as well as his Ph.D. degree in Cardiology from Medical University of Lodz, Poland.
Dr. Fossa is an internationally recognized expert in both pre-clinical and clinical evaluation of cardiac drug safety, in particular for compounds that may affect autonomic tone. His 25 years of research and drug development experience have focused on ensuring accurate characterization of drugs cardiac safety profiles using advanced continuous ECG based measurement techniques. Dr Fossa spent 25 years in the pharmaceutical industry, including 22 years at Pfizer’s early drug candidate development team. At Pfizer he held roles on numerous early Discovery/Development teams as a Research Fellow (highest scientific rank at Pfizer). Dr. Fossa was responsible for conducting in vivo preclinical cardiovascular assessments on more than 150 clinical drug candidates and was a key contributor on 5 successful commercial products (one which he is the sole patent inventor for its field of use). Dr. Fossa received Pfizer Achievement Award, the highest level of recognition for a scientist at Pfizer, for his significant contribution to development of successful commercial products. At iCardiac, Dr. Fossa provided key scientific evidence, including written and in-person communications to the regulators that lead to the recent approval of a QT-prolonging drug with a clean QT label (September 2009). Dr. Fossa was one of the original founding members of the General Pharmacology/Safety Pharmacology Steering committee, which today is known as the Safety Pharmacology Society. In that role, he served as chairman in 1996 and was responsible for organizing the annual scientific meetings from 1993 to 2000. As a scientist, he has authored a diverse range of publications related to cardiovascular assessment and is an inventor on numerous patents related to novel indications. Dr. Fossa’s research has focused on the use of beat-to-beat dynamics to assess arrhythmia liability related to human QT prolongation. His research has established in vivo models to differentiate pro-arrhythmic liability of drug candidates, with emphasis on the impact from changes in autonomic tone. Dr. Fossa is one of the four external consultants to the Cardiac Safety Research Consortium’s White Paper Working Group developing industry guidance for Holter/telemetry-based QT analyses in cardiac safety studies, addressing the limitations of current QTc analyses with respect to identification of the autonomic nervous system effects on QT interval. Dr. Fossa received his Ph.D. and M.S. in Pharmacology and Toxicology from Purdue University.
Borje Darpo is board-certified in cardiology and internal medicine. In addition to his role at iCardiac, Dr. Darpo is Associate Professor of Cardiology at the Karolinska Institute, Sweden, since 2000. He has over 11 years of industry experience, including senior management positions in small, mid-sized and large pharma, as well as a global CRO. He has led or has been responsible for projects in all phases of clinical development, including filing and approval of an NDA. Dr. Darpo authored internal QT guidance documents for the design and conduct of clinical QT assessment incl. the TQT studies, for 4 sponsors, including Pharmacia and Pfizer. Additionally, he advised 20+ sponsors on design, conduct, interpretation and regulatory communication on TQT studies for compounds within a wide range of therapeutic areas, including CV, anticoagulants, antiplatelets, metabolic, oncology and neurology and authored or co-authored 15+ TQT study protocols and CSR’s. Dr.Darpo’s experience from cardiovascular safety assessment of drugs is broad and includes participation in the generation of existent regulatory guidance on QT assessment (CPMP and ICH E14), previous co-chair of the ILSI/HESI CV safety subcommittee, member of the scientific oversight committee of CSRC, generation of internal company-specific guidances on CV safety assessment and numerous reviews of programs both internally and as a consultant. Dr. Darpo has served as the EFPIA deputy topic leader for the ICH E14 Implementation Working Group, which worked with regional implementation of this guidance and support to sponsors through a Q&A process. Dr. Darpo is a member of the Scientific Oversight Committee for the Cardiac Safety Research Consortium (CSRC) with participation from FDA, academia and EU/US industry. Additionally, Dr. Darpo is one of the four external consultants to the FDA/CSRC White Paper Working Group developing industry guidance for QT assessment of drugs that has an effect on the heart rate or on autonomic tone and for which standard QTc analyses have clear limitations.
Mr. Zapesochny is an experienced technology executive and attorney. As General Counsel and Director of Business Development for Lenel Systems International, a developer and global supplier of high-end software, products and services for the security industry, Mr. Zapesochny was part of a small executive management team that guided the company to extraordinary growth. The company expanded to serving over 10,000 organizations throughout 75 countries, including security-conscious entities such as Microsoft, Cisco, all three New York City-area airports, the Department of Homeland Security and over sixty percent of all Fortune 100 companies. The company’s financial growth earned it 39th place on Inc. magazine’s ranking of the nation’s fastest-growing privately-held companies, and Lenel was acquired for $440 million by United Technologies Corporation (NYSE: UTX) in March 2005. Mr. Zapesochny remained with UTC after the acquisition and continued in his legal and business development roles within the Lenel Systems subsidiary. In private practice, Mr. Zapesochny has provided legal and business counsel to early-stage companies. Mr. Zapesochny’s other experience includes being a trial attorney during his tenure as a New York City prosecutor, a policy division staff member in the Washington headquarters of a presidential campaign, and Co-Founder and Executive Director of an award-winning non-profit that expands the national registry of potential bone marrow and blood stem cell donors. Mr. Zapesochny received his undergraduate degree from Cornell University and graduate degrees from American University and the University of Oxford.
Prior to iCardiac Technologies, Ms. Latypova headed sales and business development at VirtualScopics, Inc. (VSCP) a leading developer of image-based biomarkers for improving pharmaceutical development. During her tenure at VirtualScopics, she expanded the client portfolio from one lead customer, Pfizer, to 6 of the top-10 pharmaceutical companies as well as multiple smaller pharmaceutical and medical device clients. In addition, she has been responsible for developing project management organization at VirtualScopics and hiring and training several project managers and business development associates. Prior to VirtualScopics, Ms. Latypova was a Manager in healthcare practice at Analysis Group, Inc., a Boston-based economics, financial and strategy consultancy, where she advised pharmaceutical clients on a wide range of issues concerning product and market development, as well as provided economic analyses and expertise in pharmaceutical litigation cases. Ms. Latypova holds Masters of Business Administration degree form the Amos Tuck School at Dartmouth College.
Mr. Baker is an experienced start-up technology executive and certified public accountant. As controller for Lenel Systems International, a developer and global supplier of high-end software, products and services for the security industry, Mr. Baker arrived at Lenel when the company was in its infancy and was an integral part of a small executive management team that guided the company from a start-up company to the dominant market leader in its industry. The company’s financial growth earned it 39th place on Inc. magazine’s ranking of the nation’s fastest-growing privately-held companies, and Lenel was acquired for $440 million by United Technologies Corporation (NYSE: UTX) in March 2005. Mr. Baker remained with UTC after the acquisition and assisted with the integration of the Lenel and UTC financial reporting systems. In April 2007, Mr. Baker joined iCardiac as its CFO. Mr. Baker enjoys working with entrepreneurs of high technology companies. Mr. Baker was Co-Founder along with Mr. Zapesochny of an award-winning non-profit that expands the national registry of potential bone marrow and blood stem cell donors. In addition to his work as a Co-Founder, Mr. Baker was selected from the Be the Match registry as a donor for a person in need of a transplant.
|
